Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary

• Lantern Pharma Inc LTRN.OQ reported a quarterly adjusted loss of 40 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -46 cents. The mean expectation of two analysts for the quarter was for a loss of 48 cents per share. Wall Street expected results to range from -53 cents to -44 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Lantern Pharma Inc's reported EPS for the quarter was a loss of 40 cents​.

• The company reported a quarterly loss of $4.33 million.

• Lantern Pharma Inc shares had risen by 40.8% this quarter and gained 39.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 8.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Lantern Pharma Inc is $20.00, about 77.8% above its last closing price of $4.45

This summary was machine generated from LSEG data August 13 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)